An antagonist of CCR9
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Vercirnon

Item No. 23131

Technical Information
Formal Name
N-[4-chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl]-4-(1,1-dimethylethyl)-benzenesulfonamide
CAS Number
698394-73-9
Synonyms
  • CCX282-B
  • GSK1605786
Molecular Formula
C22H21ClN2O4S
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMSO: 25 mg/ml
λmax
226, 313 nm
SMILES
O=C(C(C=C1)=CC=[N]1=O)C(C=C(Cl)C=C2)=C2N[S](=O)(C3=CC=C(C(C)(C)C)C=C3)=O
InChi Code
InChI=1S/C22H21ClN2O4S/c1-22(2,3)16-4-7-18(8-5-16)30(28,29)24-20-9-6-17(23)14-19(20)21(26)15-10-12-25(27)13-11-15/h4-14,24H,1-3H3
InChi Key
JRWROCIMSDXGOZ-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Product Description

    Vercirnon is an orally bioavailable antagonist of chemokine receptor 9 (CCR9) with an IC50 value of 5.4 nM for inhibition of CCL25-induced calcium mobilization in Molt-4 cells.1 It is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s = >10 µM for all). It also inhibits CCL25-induced Molt-4 chemotaxis in 0.1% BSA/HBSS and in 100% human AB serum (IC50s = 3.5 and 33.4 nM, respectively), as well as chemotaxis of human T cells stimulated by retinoic acid (RA) and mouse and rat thymocytes. Vercirnon binds allosterically to the intracellular side of CCR9 and prevents G protein coupling.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Walters, M.J., Wang, Y., Lai, N., et alCharacterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 335(1), 61-69 (2010).

    2. Oswald, C., Rappas, M., Kean, J., et alIntracellular allosteric antagonism of the CCR9 receptor. Nature 540(7633), 462-465 (2016).